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Abstract
Background: Regular use of beta-agonists leads to tolerance to their bronchodilator effects. This
can be demonstrated by measuring the response to beta-agonist following bronchoconstriction
using methacholine. However most studies have demonstrated tolerance after a period of beta-
agonist withdrawal, which is not typical of their use in clinical practice. This study assessed
tolerance to the bronchodilator action of salbutamol during ongoing treatment with long-acting
beta-agonist.
Methods: Random-order, double-blind, placebo-controlled, crossover trial. After 1 week without
beta-agonists, 13 asthmatic subjects inhaled formoterol 12 µg twice daily or matching placebo for
1 week. Eight hours after the first and last doses subjects inhaled methacholine to produce a 20%
fall in FEV1. Salbutamol 100, 200 and 400 µg (cumulative dose) was then given at 5-minute intervals
and FEV1 was measured 5 minutes after each dose. After a 1 week washout subjects crossed over
to the other treatment. Unscheduled use of beta-agonists was not allowed during the study. The
main outcome variable was the area under the salbutamol response curve.
Results:  The analysis showed a significant time by treatment interaction indicating that the
response to salbutamol fell during formoterol therapy compared to placebo. After 1 week of
formoterol the area under the salbutamol response curve was 48% (95% confidence interval 28 to
68%) lower than placebo. This reduction in response remained significant when the analyses were
adjusted for changes in the pre-challenge FEV1 and dose of methacholine given (p = 0.001).
Conclusion: The bronchodilator response to salbutamol is significantly reduced in patients taking
formoterol. Clinically relevant tolerance to rescue beta-agonist treatment is likely to occur in
patients treated with long-acting beta-agonists.
Background
Long-acting beta-agonists are often added to inhaled cor-
ticosteroids to improve asthma control.[1] Despite this,
most patients still need a short-acting beta-agonist for
relief of breakthrough symptoms. The possibility that
chronic long-acting beta-agonist use might adversely
affect the acute response to short-acting beta-agonists is
rarely considered.
It is well known that regular use of long-acting beta-ago-
nists leads to tolerance to their bronchoprotective effects
(their ability to prevent bronchoconstriction).[2,3]
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Studies looking for bronchodilator tolerance have had
more variable results.[4,5] This has led to a widespread
belief that clinically significant tolerance to bronchodila-
tion does not occur.[6] However, several recent studies
have clearly shown that bronchodilation tolerance does
occur and becomes more apparent with increasing levels
of bronchoconstriction. [7-11] This raises the possibility
that beta-agonists will be less effective during acute severe
asthma in patients using long-acting beta-agonists.
Much of the evidence for bronchodilator tolerance has
come from studies using a 'challenge-rescue model' that
measures the response to short-acting beta-agonists after
bronchoconstriction has been induced with either metha-
choline or exercise.[7-11] Testing bronchodilation from a
state of increased bronchomotor tone is thought to mimic
patients' use of beta-agonists to relieve asthma symptoms.
However, many of these studies have been performed
after a period of withdrawal from maintenance beta-ago-
nist [7,8,11] and the findings may not be relevant to
patients who continue to use their long-acting beta-ago-
nist twice daily. Other studies have been carried out at the
time of peak effect of long-acting beta-agonist, when sub-
jects are least likely to need additional bronchodilator and
when results are confounded by differing baseline levels
of bronchodilation and bronchial reactivity.[9,10]
The bronchodilator and bronchoprotective effects of
long-acting beta-agonists peak within 1 hour of inhala-
tion.[12] If they are taken twice daily as recommended
then patients will be most vulnerable to bronchoconstric-
tion and most likely to need their reliever inhalers 8–12
hours after inhalation. Tolerance to the bronchodilator
effects of these inhalers at this time is therefore of the
highest clinical relevance. Although tolerance to broncho-
protection is known to occur at this time,[3] changes in
bronchodilation using this 'challenge-rescue'[10] model
have not been studied in placebo-controlled trials.
This study was designed to assess tolerance to salbutamol
bronchodilation 8 hours after regular formoterol treat-
ment in a double-blind, randomised, placebo-controlled,
cross-over trial.
Methods
Subjects had a physician diagnosis of asthma and a PD20
methacholine (provocative dose of methacholine
required to produce a 20% fall in FEV1) <1.5 mg (<7.7
µmol). Those currently using long-acting beta-agonists
were excluded. Those who had used oral corticosteroids in
the previous 3 months or who had changed asthma treat-
ment in the previous 6 weeks were excluded, as were preg-
nant and lactating women. All subjects provided written
informed consent. Ethical approval for the study was
granted by the Waikato Ethics Committee.
After a 1-week run-in period during which no beta-ago-
nists were used, subjects were computer randomised to
receive coded bottles of capsules containing formoterol
12  µg or matching placebo for use with the Foradil
aerolizer device (Foradil, Novartis, Auckland, New Zea-
land). A methacholine challenge and salbutamol
response was performed 8 hours after the first dose of
study medication. The study medication was then taken
twice daily for 1 week. A further challenge and response
was performed 8 hours following the last dose. After a
washout period of at least 1 week the study was repeated
using the alternative medication. Use of additional beta-
agonists was not allowed throughout the study. Ipratro-
pium bromide (20 µg Atrovent metered dose inhaler,
Table 1: Baseline data on subjects.
Subject Age (years) Sex Dose of inhaled 
steroids (mcg)*
FEV1 at 1st placebo 
challenge (L)
Percent predicted 
FEV1
1 34 Female 200 3.11 100
2 40 Female 400 2.60 89
3 26 Male 1000 3.52 85
4 23 Male 0 4.32 97
5 31 Female 0 2.41 86
6 36 Male 0 4.44 107
7 31 Female 0 3.09 98
8 19 Female 0 3.83 110
9 25 Male 0 3.93 87
10 23 Female 250 2.43 73
11 60 Female 400 1.73 73
12 24 Female 0 2.87 89
13 24 Male 500 4.18 90
* budesonide equivalent (beclometasone = budesonide = 2 × fluticasone)Respiratory Research 2005, 6:107 http://respiratory-research.com/content/6/1/107
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Boehringer Ingelheim, Auckland, New Zealand) was used
for symptom relief.
Methacholine challenge was performed using a modified
Yan technique.[13] Baseline FEV1 was the highest of 3
consistent measurements. Subjects then inhaled doubling
doses of nebulised methacholine from 0.0073 mg to
3.728 mg from a dosimeter. FEV1 was measured 1 minute
after each dose. Once the FEV1 had fallen by ≥20% from
baseline, methacholine challenge was stopped. The PD20
(cumulative dose) was calculated by linear interpolation.
Where the FEV1 fell <20% from baseline (2 subjects each
on 1 occasion after formoterol) an arbitrary PD20 of 15 mg
was assigned (twice the maximum cumulative dose
given).
Salbutamol (Ventolin, GlaxoSmithKline, Auckland, New
Zealand) 100 µg, 100 µg and 200 µg via metered dose
inhaler and Volumatic spacer was given at 0, 5 and 10
minutes after challenge respectively. The FEV1 was meas-
ured 5 minutes after each dose of salbutamol, giving a
total response time of 15 minutes.
The main outcome measurement was the area under the
salbutamol response curve (AUC), expressed as a percent-
age of the methacholine-induced fall in FEV1. A secondary
outcome was the final (15-minute) FEV1 after 400 µg salb-
utamol. Previous studies indicate that the pre-metha-
choline FEV1  and dose of methacholine used are
significant covariates of the post-methacholine bron-
chodilator response [7] and analyses adjusted for these
covariates using analysis of covariance. Methacholine
doses were log-transformed for analysis to approximate a
normal distribution. The test of the hypothesis used a gen-
eral linear model with terms for subject, drug and time as
well as the covariates of pre-methacholine FEV1 and log
methacholine dose. Whether tolerance to bronchodila-
tion occurred was assessed using the drug*time interac-
tion term in the model. Post-hoc comparisons of the AUC
and final FEV1 between placebo and formoterol treat-
ments on day 1 and after 1 week of treatment used Tukey's
exact method. Comparisons of pre-challenge FEV1 and
PD20 methacholine use paired t tests. Analyses were per-
formed using Minitab 13.2 and SPSS 10.0 for Windows. All
available data were used in the main analysis. One subject
did not attend for the second placebo challenge. Exclud-
ing this subject did not significantly alter the analysis.
Results
Eighteen subjects started the run-in period. Five subjects
withdrew – one for personal reasons, one because he was
prescribed oral steroids for acute gout, two for respiratory
tract infections and one for an exacerbation of asthma.
Thirteen subjects (5 male) completed the study. One sub-
ject did not attend for the challenge after 1 week of pla-
cebo therapy. Baseline data on the subjects are presented
in table 1.
Changes in baseline FEV1 and PD20
The pre-challenge FEV1  was higher during formoterol
treatment than during placebo. This was of borderline sig-
nificance after 1 week (table 2). The first dose of
Table 2: Changes in FEV1, PD20 and fall in FEV1
Day 1 Day 8
Pre-methacholine FEV1(L) 
Mean and SD
Placebo 3.26 (0.84) 3.24 (0.86)
Formoterol 3.44 (0.80) 3.36 (0.89)
Difference (95% CI) 0.18 (0.08, 0.28) 0.12 (-0.01. 0.24)
P = 0.002 P = 0.069
PD20(mg) Geometric mean and 
95% CI for mean
Placebo 0.10 (0.04, 0.24) 0.12 (0.04, 0.32)
Formoterol 0.45 (0.15, 1.35) 0.17 (0.05, 0.60)
Difference (doubling doses) (95% 
CI)
2.12 (0.88, 3.36) 0.51 (-0.49, 1.51)
P = 0.003 P = 0.286
Fall in FEV1 from baseline (%) 
Mean and SD
Placebo 24.78 (4.74) 23.73 (4.54)
Formoterol 24.56 (5.24) 22.26 (4.34)
Difference (95% CI) -0.22 (-3.54, 3.10) -1.47 (-4.61, 1.66)
P = 0.886 P = 0.327
N = 13. As there is no data on subject 6 for day 8 placebo, data from day 1 have been used to calculate means.Respiratory Research 2005, 6:107 http://respiratory-research.com/content/6/1/107
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formoterol also increased the PD20 methacholine. After 1
week of formoterol this protection had decreased and the
PD20 was not significantly different to placebo (table 2).
Changes in salbutamol response
The area under the salbutamol response curve was lower
during formoterol therapy compared to placebo. There
was a significant time*treatment interaction indicating
that the change in salbutamol response from day 1 to day
8 of formoterol treatment was different to the change in
response from day 1 to day 8 of placebo (table 3). Com-
parisons between placebo and formoterol at each time
point found that the reduction in AUC was not statisti-
cally significant after the first dose of formoterol, after
adjusting the analysis for the increased dose of metha-
choline used. However, after 1 week of treatment the
reduction was statistically significant even after adjusting
for the dose of methacholine and the pre-challenge FEV1
(table 4). The mean difference in adjusted AUC between
the day 1 and day 8 formoterol challenges was
58.1%.time (95% confidence interval 2.7, 113.4; p =
0.04).
Despite the fact that pre-challenge FEV1 and post-metha-
choline FEV1 were higher during formoterol treatment,
the FEV1 at the end of the salbutamol dose-response was
lower on both formoterol days compared to placebo (see
figure 1 for day 8). This difference was not statistically sig-
nificant after 1 dose, but after 1 week of formoterol the
mean difference was significant after allowing for covari-
ates (table 4).
There was no effect of order of treatment on salbutamol
response, PD20  or FEV1. Analysing AUC as absolute
change in FEV1 instead of as a percentage of the fall in
FEV1 gave similar results. In this study, baseline FEV1 was
not a significant covariate in the analysis of AUC. Exclud-
ing this from the model did not materially alter the results
of the analysis. There was no difference in the change in
salbutamol response between those subjects taking and
those not taking inhaled corticosteroids.
Discussion
This study has demonstrated a marked reduction in the
bronchodilator response to salbutamol within the usual
dosing interval of standard doses of formoterol (12 µg
Table 3: ANOVA table for AUC.
Source Degrees of freedom Seq sums of squares Adjusted mean squares F P
Baseline FEV1 1 2195 0 0 0.998
Log dose methacholine 1 88136 46295 22.13 0.000
Subject 12 83869 5368 2.57 0.016
Time 1 10109 5292 2.53 0.121
Treatment 1 24752 18182 8.69 0.006
Time*treatment 1 14283 14283 6.83 0.013
Error 33
Total 50
Table 4: Differences in area under the salbutamol response curve (AUC)
Day 1 Day 8
AUC as % of fall in FEV1 
(%.time) mean and SD
Placebo 196 (74) 205 (63)
Formoterol 120 (61) 107 (53)
Difference (least squares means, 
95% confidence interval)
13.06 (-50.4, 76.53) 85.44 (31.78, 139.1)
P = 0.944 P = 0.001
Final FEV1(L) mean and SD Placebo 3.32 (0.84) 3.31 (0.89)
Formoterol 3.25 (0.22) 3.12 (0.84)
Difference (least squares means, 
95% confidence interval)
0.06 (-0.18, 0.30) 0.26 (0.06, 0.46)
P = 0.909 P = 0.006
Differences in AUC by treatment and time using Tukey's exact method from covariate analysis (n = 13)Respiratory Research 2005, 6:107 http://respiratory-research.com/content/6/1/107
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bd). After 1 week of formoterol therapy the area under the
salbutamol response curve in the formoterol arm was
nearly half that of placebo. This reduction in response was
statistically significant after adjusting for the pre-challenge
FEV1 and dose of methacholine used in the challenge
The area under the salbutamol response curve was also
reduced after a single dose of formoterol. However, this
was not statistically significant after adjusting for the dose
of methacholine used in the challenge, which was higher
after the first dose of formoterol. After 1 week of formot-
erol therapy the PD20 methacholine was not significantly
different to placebo, indicating that tolerance to broncho-
protection had occurred. Hence at this time point there
was little protection against bronchoconstriction and
greatly reduced bronchodilation.
It is known that cellular tolerance to beta-agonists occurs
very rapidly, within 8 hours in vitro, [14] so it is possible
that 'tolerance' had occurred even prior to the challenge
on day 1 of formoterol treatment. However, there may be
other explanations for a reduced response to salbutamol
during formoterol therapy, including the fact that beta2-
receptors continue to be occupied by formoterol 8 hours
after the last dose, leaving fewer receptors available to
bind salbutamol. This could explain the reduction in the
salbutamol response after the first dose of formoterol.
However, the analysis showed a significant interaction
between time and treatment, indicating that the bron-
chodilator response to salbutamol declined further during
the formoterol treatment period. Lee et al [15] also found
that the salbutamol response 1 hour after a single dose of
salmeterol or formoterol was significantly lower after 1
week of treatment than after the first dose of long-acting
beta-agonist. If receptor occupancy was the only explana-
tion for the reduction in AUC we would expect to have
found a similar reduction in AUC on the first and last day
of formoterol treatment. Moreover, the reduction in salb-
utamol response after a week of formoterol treatment
observed in this study was similar to a previous study in
our laboratory, where the salbutamol response was meas-
ured 24 hours after the last dose of formoterol.[16] Recep-
tor occupancy by formoterol would be much lower at this
time, suggesting that the reduction in response is more
likely to be due to receptor downregulation.
Regardless of the mechanism, we have shown that the
bronchodilator response to salbutamol is reduced during
long-acting beta-agonist treatment. Previous studies have
been criticised for only analysing changes in FEV1 from
baseline rather than actual post-bronchodilator levels of
FEV1.[17] It is notable in this study that the final FEV1 after
400 µg of salbutamol was lower during formoterol treat-
ment than during placebo, despite a higher pre-metha-
choline FEV1 (figure 1).
A recent meta-analysis of studies of regular beta-agonist
therapy concluded that the bronchodilator response to
subsequent beta-agonist is reduced.[18] However, most of
the individual studies included in this analysis failed to
show significant tolerance. In contrast, all of the pub-
lished trials that have measured the bronchodilator
response after methacholine challenge have shown
Response to salbutamol following methacholine challenge Figure 1
Response to salbutamol following methacholine challenge. 
Mean and standard error.
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significant tolerance.[7-9,11] The 'challenge-rescue
model' appears to be more sensitive to changes in the
response to bronchodilators. Bronchodilation is a 'closed-
end scale'[19] with a maximal achievable level. The dose-
response to beta-agonist bronchodilators is therefore
dependent on the pre-bronchodilator FEV1.[20] Subjects
with mild, stable asthma are often close to their maxi-
mum FEV1 and have little capacity for additional bron-
chodilation. Using methacholine to induce a controlled
level of bronchoconstriction before testing bronchodila-
tors ensures that there is capacity for bronchodilation and
differences in responses can be shown more easily. Since
asthmatics take bronchodilators to relieve symptoms
caused by bronchoconstriction it seems logical to test
bronchodilators from a state of bronchoconstriction.
This study is the first blinded, placebo-controlled trial to
test for bronchodilator tolerance during the trough period
of long-acting beta-agonist dosing using the 'challenge-
rescue' model. A recent non-blinded trial compared the
bronchodilator response to salbutamol after metha-
choline challenge between formoterol/budesonide or sal-
meterol/fluticasone to inhaled steroids alone, at 12 hours
after inhalation.[21] This study found a similar degree of
tolerance to the present study despite methodological dif-
ferences including the use of salbutamol as-needed.
International guidelines recommend that long-acting
beta-agonists are used only in those subjects already tak-
ing inhaled corticosteroids.[1] Not all of our subjects were
taking such medication. However, this does not detract
from the applicability of our study as it has been estab-
lished that stable doses of inhaled corticosteroids do not
alter the development of tolerance to beta-agonists.[7]
Moreover, it is widely recognised that patients are often
poorly compliant with their inhalers and it is likely that
many patients will continue to use their long-acting beta-
agonists without inhaled corticosteroids.
All but one of our subjects showed some decrease in the
bronchodilator ability of salbutamol after 1 week of for-
moterol treatment, although the magnitude of this was
variable (figure 2). The reasons for this variability are
unknown. Lee et al found that tolerance occurred to the
same extent in subjects who were homozygous for the
Arg-16 or for the Gly-16 polymorphisms of the beta2-
receptor.[15]
Conclusion
In conclusion, we have found that bronchodilator toler-
ance is present during the usual dosing interval of long-
acting beta-agonists. Wraight found that tolerance to salb-
utamol bronchodilation increased with increasing levels
of bronchoconstriction.[11] The level of bronchoconstric-
tion induced in this study (20%) was mild compared to
that likely to occur during a severe exacerbation of
asthma. Patients using long-acting beta-agonists who
experience exacerbations of asthma may have an inade-
quate response to beta-agonist relievers.
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